Latest & greatest articles for quetiapine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on quetiapine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on quetiapine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for quetiapine

21. Quetiapine more effective than placebo for depression in bipolar I and II disorder

Quetiapine more effective than placebo for depression in bipolar I and II disorder Quetiapine more effective than placebo for depression in bipolar I and II disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine more effective than placebo for depression in bipolar I and II disorder Article Text Therapeutics Quetiapine more effective than placebo for depression in bipolar I and II disorder Statistics from Altmetric.com

2008 Evidence-Based Mental Health

22. Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia

Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Article Text Therapeutics Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Statistics from

2008 Evidence-Based Mental Health

23. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (Abstract)

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia Persistent neuroleptic-induced movement disorders limit effective pharmacological management of psychotic disorders. Although antipsychotic switching is a common strategy for managing extrapyramidal side effects (EPSs), there is insufficient empirical support to guide the clinician. We designed the present study to examine whether patients with preexisting EPS switched to quetiapine (...) would show greater reduction in EPS compared with control patients.Twenty-two patients with schizophrenia meeting clinical criteria for tardive dyskinesia or coexisting parkinsonism were randomized either to switch from their current antipsychotic to quetiapine (n = 13) or to remain on their current treatment (n = 9). A battery of standard clinical assessments for EPS along with electromechanical instrumental measures was administered before randomization and again 1 and 3 months

2008 EvidenceUpdates Controlled trial quality: uncertain

24. Quetiapine for acute mania in bipolar disorder Full Text available with Trip Pro

Quetiapine for acute mania in bipolar disorder Quetiapine for acute mania in bipolar disorder Quetiapine for acute mania in bipolar disorder Brahm N C, Gutierres S L, Carnahan R M Authors' objectives To evaluate the safety and efficacy of quetiapine as a treatment for acute mania in bipolar disorder. Searching MEDLINE, Cochrane Database of Systematic Reviews, ACP Journal Club, DARE, Cochrane Controlled Trials Registry and International Pharmaceutical Abstracts databases were searched to 2006 (...) . Search terms were reported. Manufacturers' websites were searched for unpublished and ongoing trials. Study selection Randomised double-blind placebo-controlled trials (RCTs) of quetiapine for the treatment of acute mania were eligible for inclusion. The included studies evaluated quetiapine as monotherapy (400 mg/day to 800 mg/day). Some studies compared quetiapine with another pharmacological agent, such as lithium (serum concentration 0.6 meq/L to 1.4 meq/L) and haloperidol (4 mg/day to 8 mg/day

2007 DARE.

25. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

26. Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials Full Text available with Trip Pro

Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials Caro J J, Huybrechts K F, Xenakis J G, O'Brien J A, Rajagopalan K, Lee K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined quetiapine, an atypical antipsychotic for the treatment of bipolar mania. Different scenarios were considered on the basis of the proportion of patients using quetiapine with respect to other standard

2006 NHS Economic Evaluation Database.

27. Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Full Text available with Trip Pro

Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Article Text Therapeutics

2006 Evidence-Based Mental Health

28. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Full Text available with Trip Pro

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance.Randomised double blind (clinician, patient, outcomes assessor) placebo controlled trial.Care facilities in the north east of England.93 patients with Alzheimer's (...) disease, dementia, and clinically significant agitation.Atypical antipsychotic (quetiapine), cholinesterase inhibitor (rivastigmine), or placebo (double dummy).Agitation (Cohen-Mansfield agitation inventory) and cognition (severe impairment battery) at baseline and at six weeks and 26 weeks. The primary outcome was agitation inventory at six weeks.31 patients were randomised to each group, and 80 (86%) started treatment (25 rivastigmine, 26 quetiapine, 29 placebo), of whom 71 (89%) tolerated

2005 BMJ Controlled trial quality: predicted high

29. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Kongsakon R, Leelahanaj T, Price N (...) , Birinyi-Strachan L, Davey P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several medications for schizophrenia were examined. The four atypical antipsychotics studied were olanzapine (OLZ), risperidone (RISP), quetiapine (QUET

2005 NHS Economic Evaluation Database.

30. Quetiapine for schizophrenia. Full Text available with Trip Pro

Quetiapine for schizophrenia. Quetiapine is an atypical antipsychotic with, theoretically, a low propensity for movement disorder adverse effects. It is used for the treatment of schizophrenia and other psychoses.To determine the effects of quetiapine for schizophrenia in comparison to placebo, and other antipsychotics.Electronic searches of the Cochrane Schizophrenia Group's Register of Trials (February 2003), Biological Abstracts (1982-2000), CINAHL (1982-2000), the Cochrane Library (2000 (...) , Issue 1),EMBASE (1980-2000), MEDLINE (1966-2000), PsycLIT (1974-2000), SIGLE on CD (1980-1997), SocioFile (1974-1997) and many conference proceedings and hand searches of specific journals were undertaken. We contacted AstraZeneca Pharmaceuticals for information regarding unpublished trials. The review was updated in February 2003.All randomised controlled trials where adults with schizophrenia or similar illnesses were assigned to quetiapine, placebo or other neuroleptic drugs and where clinically

2004 Cochrane

31. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics

An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics Tilden D, Aristides M, Meddis D, Burns T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of quetiapine versus haloperidol for the treatment of patients with schizophrenia who were only partially responsive to conventional antipsychotics. Type of intervention Treatment. Economic study type Cost

2002 NHS Economic Evaluation Database.

32. The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia Lynch J, Morrison J, Graves N, Meddis D, Drummond M F, Hellewell J S E Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of quetiapine ('Seroquel'), a new atypical antipsychotic, in patients with chronic schizophrenia. The dosage was 150 to 750 mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness

2001 NHS Economic Evaluation Database.

33. Quetiapine for schizophrenia. (Abstract)

Quetiapine for schizophrenia. Quetiapine is a novel atypical antipsychotic with low propensity for movement disorder adverse effects. It is used for treatment of schizophrenia and other psychoses.To determine the effects of quetiapine for schizophrenia in comparison to placebo, classical and other atypical antipsychotics.Electronic searches of Biological Abstracts (1982-1997), CINAHL (1982-1997), the Cochrane Library (1998, Issue 1), the Cochrane Schizophrenia Group's Register of trials (1998 (...) ), EMBASE (1980-1998), MEDLINE (1966-1998), PsycLIT (1974-1997), SocioFile (1974-1997) and many conference proceedings and hand searches of specific journals were undertaken. Zeneca Pharmaceuticals was contacted for information regarding unpublished trials.All controlled trials where adults with schizophrenia or similar illnesses were randomised to quetiapine, placebo or other neuroleptic drugs and where clinically relevant outcomes were reported.Citations and, where possible, abstracts were

2000 Cochrane

34. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Efficacy and extrapyramidal side-effects of the new (...) antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Leucht S, Pitschel-Walz G, Abraham D, Kissling W Authors' objectives To summarise the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics. Searching MEDLINE (1966-January 1998) and Current Contents (1966-March 1998) were

1999 DARE.